Close Menu

NEW YORK (GenomeWeb) – Agendia said today that Belgium's University Hospitals Leuven has agreed to participate in a co-validation effort for an in vitro diagnostic kit version of the company's MammaPrint and BluePrint breast cancer assays.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.